Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CM93 |
| Synonyms | |
| Therapy Description |
CM93 is a blood-brain-barrier penetrant third-generation EGFR inhibitor, with activity against EGFR mutations, which decreases downstream signaling potentially resulting in increased death of EGFR-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CM93 | CM 93|CM-93 | EGFR Inhibitor 3rd gen 28 | CM93 is a blood-brain-barrier penetrant third-generation EGFR inhibitor, with activity against EGFR mutations, which decreases downstream signaling potentially resulting in increased death of EGFR-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|